BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Inflammatory Bowel Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Inflammatory Bowel Di
 sease\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06456593-18@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:obefazimod: Phase 2 readout est. (NCT06456593)
DESCRIPTION:obefazimod\, phase 2\, Crohn's Disease.\nStudy: Efficacy and Sa
 fety of Obefazimod in Subjects With Moderately to Severely Active Crohn's 
 Disease\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obefazimod#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06456593
URL:https://assetmemo.bio/drug/obefazimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229950-30@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-7085: Phase 2 readout est. (NCT07229950)
DESCRIPTION:HRS-7085\, phase 2\, Ulcerative Colitis.\nStudy: A Phase 2 Clin
 ical Study to Evaluate the Efficacy\, Safety\, and Pharmacokinetics of HRS
 -7085 Tablets in Patients With Inflammatory Bowel Disease\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/hrs-7085#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07229950
URL:https://assetmemo.bio/drug/hrs-7085#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925594-86@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:TH-SC01: Phase 3 readout est. (NCT06925594)
DESCRIPTION:TH-SC01\, phase 3\, Crohn's Disease.\nStudy: Phase 3 Study of H
 uman TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients Wit
 h Crohn's Disease\nEstimated primary completion: 28 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/th-sc01#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06925594
URL:https://assetmemo.bio/drug/th-sc01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05486104-54@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Mufemilast: Phase 2 readout est. (NCT05486104)
DESCRIPTION:Mufemilast\, phase 2\, Ulcerative Colitis.\nStudy: Phase II Stu
 dy of Hemay005 in Patients With Active Ulcerative Colitis\nEstimated prima
 ry completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/mufemilast#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05486104
URL:https://assetmemo.bio/drug/mufemilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910528-20@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:afimkibart: Phase 2 readout est. (NCT05910528)
DESCRIPTION:afimkibart\, phase 2\, Crohn's Disease.\nStudy: Afimkibart (RO7
 790121) for the Treatment of Moderate to Severe Active Crohn's Disease\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05910528
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149467-12@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07149467)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: Uste
 kinumab and Upadacitinib for Induction and Maintenance Therapy in Patients
  With Refractory Crohn's Disease: A Multicenter\, Randomized\, Parallel-Co
 ntrolled Study\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07149467
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589986-20@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:afimkibart: Phase 3 readout est. (NCT06589986)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to A
 ssess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for 
 Induction and Maintenance Therapy in Participants With Moderately to Sever
 ely Active Ulcerative Colitis\nEstimated primary completion: 30 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/afimkibart#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06589986
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06260163-5@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06260163)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Ulcerative Colitis.\nStudy: A 
 Study of Guselkumab in Pediatric Participants With Moderately to Severely 
 Active Ulcerative Colitis\nEstimated primary completion: 10 February 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06260163
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06063967-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT06063967)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy to Assess Adverse Events and Change in Disease Activity of Risankizum
 ab Subcutaneous Induction Treatment for Moderately to Severely Active Croh
 n's Disease.\nEstimated primary completion: March 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06063967
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624230-15@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270318
SUMMARY:Xeljanz (tofacitinib): Phase 3 readout est. (NCT04624230)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: E
 valuation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering
  From Moderate to Severe Ulcerative Colitis\nEstimated primary completion:
  17 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tofac
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04624230
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05347095-5@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT05347095)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab in Participants With Fistulizing\, Perianal Crohn's Disea
 se\nEstimated primary completion: 25 March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05347095
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113522-46@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:MT-501: Phase 2 readout est. (NCT07113522)
DESCRIPTION:MT-501\, phase 2\, Ulcerative Colitis.\nStudy: A Phase 2 Study 
 to Evaluate Therapies for Inflammatory Bowel Disease\nEstimated primary co
 mpletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/mt-501#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07113522
URL:https://assetmemo.bio/drug/mt-501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113522-47@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:MT-201: Phase 2 readout est. (NCT07113522)
DESCRIPTION:MT-201\, phase 2\, Ulcerative Colitis.\nStudy: A Phase 2 Study 
 to Evaluate Therapies for Inflammatory Bowel Disease\nEstimated primary co
 mpletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/mt-201#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07113522
URL:https://assetmemo.bio/drug/mt-201#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07186101-4@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Omvoh (mirikizumab): Phase 2 readout est. (NCT07186101)
DESCRIPTION:Omvoh (mirikizumab)\, phase 2\, Ulcerative Colitis.\nStudy: LY4
 268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderate
 ly to Severely Active Ulcerative Colitis:\nEstimated primary completion: M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/mirikizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0718
 6101
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07186101-21@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Zotemtegrast: Phase 2 readout est. (NCT07186101)
DESCRIPTION:Zotemtegrast\, phase 2\, Ulcerative Colitis.\nStudy: LY4268989 
 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to S
 everely Active Ulcerative Colitis:\nEstimated primary completion: May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/zotemtegrast#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07186101
URL:https://assetmemo.bio/drug/zotemtegrast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660693-12@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06660693)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: C
 omparison of Medical RESCUE Strategies for Patients With Steroid-refractor
 y Acute Severe Ulcerative Colitis\nEstimated primary completion: May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06660693
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012395-26@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SPY001: Phase 2 readout est. (NCT07012395)
DESCRIPTION:SPY001\, phase 2\, Ulcerative Colitis.\nStudy: A Study of Long-
 acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerat
 ive Colitis\nEstimated primary completion: June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/spy001#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07012395
URL:https://assetmemo.bio/drug/spy001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012395-27@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SPY002: Phase 2 readout est. (NCT07012395)
DESCRIPTION:SPY002\, phase 2\, Ulcerative Colitis.\nStudy: A Study of Long-
 acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerat
 ive Colitis\nEstimated primary completion: June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/spy002#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07012395
URL:https://assetmemo.bio/drug/spy002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012395-28@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SPY003: Phase 2 readout est. (NCT07012395)
DESCRIPTION:SPY003\, phase 2\, Ulcerative Colitis.\nStudy: A Study of Long-
 acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerat
 ive Colitis\nEstimated primary completion: June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/spy003#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07012395
URL:https://assetmemo.bio/drug/spy003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625293-50@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:ExoFlo: Phase 2 readout est. (NCT07625293)
DESCRIPTION:ExoFlo\, phase 2\, Crohn's Disease.\nStudy: DB-3Q for the Treat
 ment of Medically Refractory Crohn's Disease\nEstimated primary completion
 : June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exoflo#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07625
 293
URL:https://assetmemo.bio/drug/exoflo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06408935-5@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06408935)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: Trans
 mural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Diseas
 e Patients\nEstimated primary completion: 8 June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06408935
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227910-7@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06227910)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Di
 sease\nEstimated primary completion: 8 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06227910
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227910-12@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06227910)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Di
 sease\nEstimated primary completion: 8 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06227910
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006068-12@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT03006068)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-
 494) in Participants With Ulcerative Colitis (UC)\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upa
 dacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03006068
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725017-83@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Live SK08: Phase 2 readout est. (NCT06725017)
DESCRIPTION:Live SK08\, phase 2\, Ulcerative Colitis.\nStudy: A Phase 2 Stu
 dy to Evaluate the Efficacy and Safety of Live SK08 Powder in Adult Patien
 ts with Active Mild to Moderate Ulcerative Colitis\nEstimated primary comp
 letion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 live-sk08#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06725017
URL:https://assetmemo.bio/drug/live-sk08#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06636656-43@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:BI 3032950: Phase 2 readout est. (NCT06636656)
DESCRIPTION:BI 3032950\, phase 2\, Ulcerative Colitis.\nStudy: A Study to T
 est Whether BI 3032950 Helps People With Ulcerative Colitis\nEstimated pri
 mary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bi-3032950#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06636656
URL:https://assetmemo.bio/drug/bi-3032950#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918808-50@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:ExoFlo: Phase 2 readout est. (NCT06918808)
DESCRIPTION:ExoFlo\, phase 2\, Crohn's Disease.\nStudy: DB-3Q bmMSC-EVs in 
 Patients With Perianal Fistulizing Crohn's Disease\nEstimated primary comp
 letion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /exoflo#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06918808
URL:https://assetmemo.bio/drug/exoflo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232576-31@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07232576)
DESCRIPTION:SHR-1139\, phase 2\, Ulcerative Colitis.\nStudy: A Phase 2 Stud
 y to Evaluate the Efficacy\, Safety and Pharmacokinetics of SHR-1139 in Pa
 tients With Moderate-to-severe Active Ulcerative Colitis\nEstimated primar
 y completion: August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/shr-1139#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07232576
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880744-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT06880744)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Assess the Change in Disease Activity in Adult Participants Wit
 h Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared
  to Vedolizumab\nEstimated primary completion: August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06880744
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880744-7@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06880744)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study to Assess the Change in Disease Activity in Adult Participants With
  Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared 
 to Vedolizumab\nEstimated primary completion: August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06880744
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07265570-40@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:garutadustat: Phase 2 readout est. (NCT07265570)
DESCRIPTION:garutadustat\, phase 2\, Ulcerative Colitis.\nStudy: Study Eval
 uating ISM5411 Administered Orally to Subjects With Active Ulcerative Coli
 tis (BETHESDA)\nEstimated primary completion: 15 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/garutadustat#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07265570
URL:https://assetmemo.bio/drug/garutadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979336-44@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:vixarelimab: Phase 2 readout est. (NCT06979336)
DESCRIPTION:vixarelimab\, phase 2\, Ulcerative Colitis.\nStudy: A Study to 
 Evaluate the Efficacy\, Safety\, and Pharmacokinetics (PK) of RO7837195 in
  Participants With Moderately to Severely Active Ulcerative Colitis (UC)\n
 Estimated primary completion: 25 August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/vixarelimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06979336
URL:https://assetmemo.bio/drug/vixarelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06257875-8@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT06257875)
DESCRIPTION:Humira (adalimumab)\, phase 2\, Ulcerative Colitis.\nStudy: A S
 tudy to Assess Adverse Events and Change in Disease Activity From Intraven
 ous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Acti
 ve Ulcerative Colitis\nEstimated primary completion: September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06257875
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03345823-12@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT03345823)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: A Ma
 intenance and Long-Term Extension Study of the Efficacy and Safety of Upad
 acitinib (ABT-494) in Participants With Crohn's Disease Who Completed the 
 Studies M14-431 or M14-433\nEstimated primary completion: September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03345823
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04779320-7@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT04779320)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn
 's Disease (CD)\nEstimated primary completion: 13 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04779320
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03221036-7@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT03221036)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: E
 fficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerati
 ve Colitis\nEstimated primary completion: 24 September 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03221036
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05092269-6@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Stelara (ustekinumab): Phase 3 readout est. (NCT05092269)
DESCRIPTION:Stelara (ustekinumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Long-term Extension Study of Ustekinumab in Pediatric Participants\nEstim
 ated primary completion: 29 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ustekinumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05092269
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04224558-4661@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT04224558)
DESCRIPTION:Methylprednisolone\, phase 1/2\, Crohn's Disease.\nStudy: Stem 
 Cell Transplantation in Crohn's Disease\nEstimated primary completion: 30 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methy
 lprednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04224558
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845487-32@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:PALI-2108: Phase 2 readout est. (NCT07845487)
DESCRIPTION:PALI-2108\, phase 2\, Ulcerative Colitis.\nStudy: A Trial to In
 vestigate PALI-2108 Versus Placebo in Participants With Moderately to Seve
 rely Active Ulcerative Colitis\nEstimated primary completion: October 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pali-2108#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07845487
URL:https://assetmemo.bio/drug/pali-2108#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335055-64@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:HSK47388: Phase 2 readout est. (NCT07335055)
DESCRIPTION:HSK47388\, phase 2\, Ulcerative Colitis.\nStudy: A Study for HS
 K47388 in Participants With Ulcerative Colitis\nEstimated primary completi
 on: 15 October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 hsk47388#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07335055
URL:https://assetmemo.bio/drug/hsk47388#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05923073-5@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271027
DTEND;VALUE=DATE:20271028
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT05923073)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab in Pediatric Participants With Moderately to Severely Act
 ive Crohn's Disease\nEstimated primary completion: 27 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05923073
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463183-75@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:MK-8690: Phase 2 readout est. (NCT07463183)
DESCRIPTION:MK-8690\, phase 2\, Ulcerative Colitis.\nStudy: A Study to Eval
 uate Efficacy and Safety of MK-8690 in Participants With Moderately to Sev
 erely Active Ulcerative Colitis (MK-8690-002)\nEstimated primary completio
 n: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 k-8690#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07463183
URL:https://assetmemo.bio/drug/mk-8690#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755241-60@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:AC-101: Phase 2 readout est. (NCT07755241)
DESCRIPTION:AC-101\, phase 2\, Ulcerative Colitis.\nStudy: A Study of AC-10
 1 Tablets in Patients With Ulcerative Colitis\nEstimated primary completio
 n: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ac-101#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07755241
URL:https://assetmemo.bio/drug/ac-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06619990-69@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:XmAb942: Phase 1/2 readout est. (NCT06619990)
DESCRIPTION:XmAb942\, phase 1/2\, Ulcerative Colitis.\nStudy: Study of XmAb
 942 in Healthy Participants and Participants With Ulcerative Colitis\nEsti
 mated primary completion: December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/xmab942#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06619990
URL:https://assetmemo.bio/drug/xmab942#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05509777-4@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT05509777)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Crohn's Disease.\nStudy: A Stud
 y of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Diseas
 e\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/mirikizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05509777
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258641-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Skyrizi (risankizumab): Phase 1/2 readout est. (NCT07258641)
DESCRIPTION:Skyrizi (risankizumab)\, phase 1/2\, Ulcerative Colitis.\nStudy
 : Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Infla
 mmatory Bowel Disease\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07258641
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258641-8@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Humira (adalimumab): Phase 1/2 readout est. (NCT07258641)
DESCRIPTION:Humira (adalimumab)\, phase 1/2\, Ulcerative Colitis.\nStudy: F
 luorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflamma
 tory Bowel Disease\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07258641
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196748-19@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280114
DTEND;VALUE=DATE:20280115
SUMMARY:Icotyde (icotrokinra): Phase 3 readout est. (NCT07196748)
DESCRIPTION:Icotyde (icotrokinra)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With
  Moderately to Severely Active Ulcerative Colitis\nEstimated primary compl
 etion: 14 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/icotrokinra#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07196748
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524611-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT04524611)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: Stu
 dy Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Uste
 kinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult
  Participants With Moderate to Severe Crohn's Disease (CD)\nEstimated prim
 ary completion: February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/risankizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04524611
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05177835-18@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:obefazimod: Phase 2 readout est. (NCT05177835)
DESCRIPTION:obefazimod\, phase 2\, Ulcerative Colitis.\nStudy: Long-term Sa
 fety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Ac
 tive Ulcerative Colitis\nEstimated primary completion: March 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/obefazimod#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05177835
URL:https://assetmemo.bio/drug/obefazimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937086-4@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT06937086)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Ulcerative Colitis.\nStudy: Mir
 ikizumab Administered at the Same Time as Tirzepatide in Adult Participant
 s With Moderately to Severely Active Ulcerative Colitis and Obesity or Ove
 rweight: Phase 3b Study\nEstimated primary completion: April 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/mirikizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06937086
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07544160-85@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280407
DTEND;VALUE=DATE:20280408
SUMMARY:ICG318: Phase 1/2 readout est. (NCT07544160)
DESCRIPTION:ICG318\, phase 1/2\, Ulcerative Colitis.\nStudy: BCMA-CD19 cCAR
  T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)\nEstim
 ated primary completion: 7 April 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/icg318#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07544160
URL:https://assetmemo.bio/drug/icg318#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614387-7@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06614387)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: V
 edolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab\nEs
 timated primary completion: 30 April 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06614387
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614387-9@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Remicade (infliximab): Phase 3 readout est. (NCT06614387)
DESCRIPTION:Remicade (infliximab)\, phase 3\, Ulcerative Colitis.\nStudy: V
 edolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab\nEs
 timated primary completion: 30 April 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06614387
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650942-54@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Mufemilast: Phase 3 readout est. (NCT07650942)
DESCRIPTION:Mufemilast\, phase 3\, Ulcerative Colitis.\nStudy: Hemay005 for
  the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
 \nEstimated primary completion: May 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/mufemilast#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07650942
URL:https://assetmemo.bio/drug/mufemilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937099-4@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT06937099)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Crohn's Disease.\nStudy: Miriki
 zumab and Tirzepatide Administered in Adult Participants With Moderately t
 o Severely Active Crohn's Disease and Obesity or Overweight\nEstimated pri
 mary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/mirikizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06937099
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937099-11052@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06937099)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Crohn's Disease.\nStudy: Mir
 ikizumab and Tirzepatide Administered in Adult Participants With Moderatel
 y to Severely Active Crohn's Disease and Obesity or Overweight\nEstimated 
 primary completion: May 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06937099
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184996-1@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184996)
DESCRIPTION:duvakitug\, phase 3\, Ulcerative Colitis.\nStudy: An Induction 
 Study to Investigate the Efficacy and Safety of Duvakitug in Participants 
 With Moderately to Severely Active Ulcerative Colitis\nEstimated primary c
 ompletion: 9 May 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/duvakitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07184996
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06100289-7@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280516
DTEND;VALUE=DATE:20280517
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06100289)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or
  Crohn's Disease\nEstimated primary completion: 16 May 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06100289
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846683-20@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:afimkibart: Phase 3 readout est. (NCT07846683)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to A
 ssess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimk
 ibart in Participants With Moderately to Severely Active Ulcerative Coliti
 s\nEstimated primary completion: 31 May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07846683
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07577843-22@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280612
DTEND;VALUE=DATE:20280613
SUMMARY:JNJ-78934804: Phase 3 readout est. (NCT07577843)
DESCRIPTION:JNJ-78934804\, phase 3\, Crohn's Disease.\nStudy: A Study of JN
 J-78934804 in Participants With Moderately to Severely Active Crohn's Dise
 ase\nEstimated primary completion: 12 June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/jnj-78934804#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07577843
URL:https://assetmemo.bio/drug/jnj-78934804#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177118-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280620
DTEND;VALUE=DATE:20280621
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT07177118)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 Risankizumab for Fibrostenotic Crohn's Disease Treatment\nEstimated primar
 y completion: 20 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/risankizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07177118
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374471-56@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:MB-001: Phase 1/2 readout est. (NCT07374471)
DESCRIPTION:MB-001\, phase 1/2\, Ulcerative Colitis.\nStudy: A Study of MB-
 001 in Moderately to Severely Active Ulcerative Colitis\nEstimated primary
  completion: July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/mb-001#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07374471
URL:https://assetmemo.bio/drug/mb-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05782907-12@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05782907)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: S
 tudy to Assess Adverse Events\, Change in Disease Activity\, and How Oral 
 Upadacitinib Moves Through the Body of Pediatric Participants With Moderat
 ely to Severely Active Ulcerative Colitis.\nEstimated primary completion: 
 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadacit
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05782907
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07577856-22@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280811
DTEND;VALUE=DATE:20280812
SUMMARY:JNJ-78934804: Phase 3 readout est. (NCT07577856)
DESCRIPTION:JNJ-78934804\, phase 3\, Ulcerative Colitis.\nStudy: A Study of
  JNJ-78934804 in Participants With Moderately to Severely Active Ulcerativ
 e Colitis\nEstimated primary completion: 11 August 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/jnj-78934804#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07577856
URL:https://assetmemo.bio/drug/jnj-78934804#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06226883-21@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zotemtegrast: Phase 2 readout est. (NCT06226883)
DESCRIPTION:Zotemtegrast\, phase 2\, Crohn's Disease.\nStudy: A Phase 2 Stu
 dy to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn
 's Disease\nEstimated primary completion: September 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/zotemtegrast#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06226883
URL:https://assetmemo.bio/drug/zotemtegrast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03398135-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT03398135)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Assess the Efficacy and Safety of Risankizumab in Participants 
 With Ulcerative Colitis\nEstimated primary completion: September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03398135
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196722-19@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Icotyde (icotrokinra): Phase 2/3 readout est. (NCT07196722)
DESCRIPTION:Icotyde (icotrokinra)\, phase 2/3\, Crohn's Disease.\nStudy: A 
 Study of Icotrokinra in Participants With Moderately to Severely Active Cr
 ohn's Disease\nEstimated primary completion: 19 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/icotrokinra#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07196722
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185009-1@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280921
DTEND;VALUE=DATE:20280922
SUMMARY:duvakitug: Phase 3 readout est. (NCT07185009)
DESCRIPTION:duvakitug\, phase 3\, Ulcerative Colitis.\nStudy: A Maintenance
  Study to Investigate the Efficacy and Safety of Duvakitug in Participants
  With Moderately to Severely Active Ulcerative Colitis\nEstimated primary 
 completion: 21 September 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/duvakitug#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07185009
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03219359-7@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Entyvio (vedolizumab): Phase 2 readout est. (NCT03219359)
DESCRIPTION:Entyvio (vedolizumab)\, phase 2\, Crohn's Disease.\nStudy: Auto
 logous Stem Cell Transplant for Crohn's Disease\nEstimated primary complet
 ion: October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 dolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03219359
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03219359-4661@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT03219359)
DESCRIPTION:Methylprednisolone\, phase 2\, Crohn's Disease.\nStudy: Autolog
 ous Stem Cell Transplant for Crohn's Disease\nEstimated primary completion
 : October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methy
 lprednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03219359
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06430801-2@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:tulisokibart: Phase 3 readout est. (NCT06430801)
DESCRIPTION:tulisokibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Ev
 aluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants W
 ith Moderate to Severe Crohn's Disease (MK-7240-008)\nEstimated primary co
 mpletion: 30 October 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tulisokibart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06430801
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499232-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT07499232)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy of Guselkumab Versus Risankizumab in Participants With Moderately to 
 Severely Active Crohn's Disease\nEstimated primary completion: 15 November
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07499
 232
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499232-5@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT07499232)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab Versus Risankizumab in Participants With Moderately to Se
 verely Active Crohn's Disease\nEstimated primary completion: 15 November 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07499232
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535489-80@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:IPG11406: Phase 2 readout est. (NCT07535489)
DESCRIPTION:IPG11406\, phase 2\, Ulcerative Colitis.\nStudy: Efficacy and S
 afety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Pha
 se 2)\nEstimated primary completion: 1 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ipg11406#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07535489
URL:https://assetmemo.bio/drug/ipg11406#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513181-24@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:ATH-063: Phase 2 readout est. (NCT07513181)
DESCRIPTION:ATH-063\, phase 2\, Ulcerative Colitis.\nStudy: Proof of Concep
 t Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patient
 s With Relapsed/Refractory Moderately to Severely Active Ulcerative Coliti
 s (UC)\nEstimated primary completion: 14 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ath-063#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07513181
URL:https://assetmemo.bio/drug/ath-063#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819878-20@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:afimkibart: Phase 3 readout est. (NCT06819878)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Efficacy and Safety of Induction and Maintenance Therapy With Afimk
 ibart (RO7790121) in Participants With Moderately to Severely Active Crohn
 's Disease\nEstimated primary completion: 31 December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06819878
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819891-20@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:afimkibart: Phase 3 readout est. (NCT06819891)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121
 ) in Participants With Moderately to Severely Active Crohn's Disease\nEsti
 mated primary completion: 31 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06819891
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03105102-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT03105102)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy of the Efficacy and Safety of Risankizumab in Participants With Crohn
 's Disease\nEstimated primary completion: February 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03105102
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507513-53@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:SSGJ-627: Phase 2 readout est. (NCT07507513)
DESCRIPTION:SSGJ-627\, phase 2\, Ulcerative Colitis.\nStudy: The Purpose of
  This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment
  of UC\nEstimated primary completion: 28 February 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ssgj-627#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07507513
URL:https://assetmemo.bio/drug/ssgj-627#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652294-26@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:SPY001: Phase 2 readout est. (NCT07652294)
DESCRIPTION:SPY001\, phase 2\, Ulcerative Colitis.\nStudy: Long-term Safety
  and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations
  for IBD\nEstimated primary completion: 2 March 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/spy001#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07652294
URL:https://assetmemo.bio/drug/spy001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652294-27@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:SPY002: Phase 2 readout est. (NCT07652294)
DESCRIPTION:SPY002\, phase 2\, Ulcerative Colitis.\nStudy: Long-term Safety
  and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations
  for IBD\nEstimated primary completion: 2 March 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/spy002#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07652294
URL:https://assetmemo.bio/drug/spy002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652294-28@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:SPY003: Phase 2 readout est. (NCT07652294)
DESCRIPTION:SPY003\, phase 2\, Ulcerative Colitis.\nStudy: Long-term Safety
  and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations
  for IBD\nEstimated primary completion: 2 March 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/spy003#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07652294
URL:https://assetmemo.bio/drug/spy003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05995353-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT05995353)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy to Assess Adverse Events\, Change in Disease Activity\, and How Intra
 venous and Subcutaneous Risankizumab Moves Through the Body of Pediatric P
 articipants With Moderately to Severely Active Crohn's Disease\nEstimated 
 primary completion: April 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/risankizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05995353
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686081-1919@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Ponesimod: Phase 3 readout est. (NCT07686081)
DESCRIPTION:Ponesimod\, phase 3\, Ulcerative Colitis.\nStudy: Study to Eval
 uate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moder
 ately to Severely Active Ulcerative Colitis\nEstimated primary completion:
  April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ponesimo
 d#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 686081
URL:https://assetmemo.bio/drug/ponesimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184931-1@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290514
DTEND;VALUE=DATE:20290515
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184931)
DESCRIPTION:duvakitug\, phase 3\, Crohn's Disease.\nStudy: An Induction Stu
 dy to Investigate the Efficacy and Safety of Duvakitug in Participants Wit
 h Moderately to Severely Active Crohn's Disease\nEstimated primary complet
 ion: 14 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duv
 akitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07184931
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05287126-13@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290616
DTEND;VALUE=DATE:20290617
SUMMARY:Velsipity (etrasimod): Phase 2 readout est. (NCT05287126)
DESCRIPTION:Velsipity (etrasimod)\, phase 2\, Ulcerative Colitis.\nStudy: A
  Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Coli
 tis\nEstimated primary completion: 16 June 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/etrasimod#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05287126
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03950232-13@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290619
DTEND;VALUE=DATE:20290620
SUMMARY:Velsipity (etrasimod): Phase 3 readout est. (NCT03950232)
DESCRIPTION:Velsipity (etrasimod)\, phase 3\, Ulcerative Colitis.\nStudy: A
 n Extension Study for Treatment of Moderately to Severely Active Ulcerativ
 e Colitis\nEstimated primary completion: 19 June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/etrasimod#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03950232
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184944-1@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290813
DTEND;VALUE=DATE:20290814
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184944)
DESCRIPTION:duvakitug\, phase 3\, Crohn's Disease.\nStudy: A Maintenance St
 udy to Investigate the Efficacy and Safety of Duvakitug in Participants Wi
 th Moderately to Severely Active Crohn's Disease\nEstimated primary comple
 tion: 13 August 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /duvakitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07184944
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548542-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT06548542)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Crohn's Disease.\nStudy: Stu
 dy of Targeted Therapies for the Treatment of Adult Participants With Mode
 rate to Severe Crohn's Disease\nEstimated primary completion: January 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06548542
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05837897-7@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300308
DTEND;VALUE=DATE:20300309
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT05837897)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab in Adult Participants With Moderate to Severe Crohn's D
 isease\nEstimated primary completion: 8 March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05837897
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158242-20@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:afimkibart: Phase 3 readout est. (NCT07158242)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to E
 valuate the Pharmacokinetics\, Safety and Efficacy of Afimkibart (RO779012
 1) in Children With Moderately to Severely Active Ulcerative Colitis\nEsti
 mated primary completion: 31 March 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07158242
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298421-20@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:afimkibart: Phase 3 readout est. (NCT07298421)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Pharmacokinetics\, Effectiveness and Safety of Afimkibart for Induc
 tion and Maintenance Therapy in Children With Moderately to Severely Activ
 e Crohn's Disease\nEstimated primary completion: 31 May 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07298421
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415044-21@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Zotemtegrast: Phase 2 readout est. (NCT07415044)
DESCRIPTION:Zotemtegrast\, phase 2\, Ulcerative Colitis.\nStudy: LY4268989 
 in Adults With Moderately to Severely Active Ulcerative Colitis\nEstimated
  primary completion: June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zotemtegrast#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07415044
URL:https://assetmemo.bio/drug/zotemtegrast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06405087-7@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300812
DTEND;VALUE=DATE:20300813
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06405087)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Long-Term Extension Study of Vedolizumab in Children and Teenagers With U
 lcerative Colitis (UC) or Crohn's Disease (CD)\nEstimated primary completi
 on: 12 August 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 edolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06405087
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07470879-13@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300908
DTEND;VALUE=DATE:20300909
SUMMARY:Velsipity (etrasimod): Phase 2 readout est. (NCT07470879)
DESCRIPTION:Velsipity (etrasimod)\, phase 2\, Ulcerative Colitis.\nStudy: A
  Study of How the Medicine Called "Etrasimod" Works in Children With the G
 ut Disease Called Ulcerative Colitis\nEstimated primary completion: 8 Sept
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etrasimod
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 70879
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04844606-4@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT04844606)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A M
 aster Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Par
 ticipants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)\nEstimated
  primary completion: December 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/mirikizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04844606
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06332534-12@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06332534)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: Croh
 n's Disease: Efficacy\, Safety\, and Pharmacokinetics of Upadacitinib in P
 ediatric Subjects With Moderately to Severely Active Crohn's Disease\nEsti
 mated primary completion: January 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06332534
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697456-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT07697456)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Ulcerative Colitis.\nStudy: 
 Study of Advanced Therapies for the Treatment of Adult Participants With M
 oderately to Severely Active Crohn's Disease or Ulcerative Colitis\nEstima
 ted primary completion: October 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/risankizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07697456
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663332-5@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20311212
DTEND;VALUE=DATE:20311213
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06663332)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Ulcerative Colitis.\nStudy: A 
 Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants\nE
 stimated primary completion: 12 December 2031. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06663332
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076175-14@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20320712
DTEND;VALUE=DATE:20320713
SUMMARY:Zeposia (ozanimod): Phase 2/3 readout est. (NCT05076175)
DESCRIPTION:Zeposia (ozanimod)\, phase 2/3\, Ulcerative Colitis.\nStudy: A 
 Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With
  Moderate to Severe Active Ulcerative Colitis\nEstimated primary completio
 n: 12 July 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ozan
 imod#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05076175
URL:https://assetmemo.bio/drug/ozanimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05442567-7@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20330207
DTEND;VALUE=DATE:20330208
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT05442567)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's 
 Disease (CD)\nEstimated primary completion: 7 February 2033. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05442567
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071519-3@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20340731
DTEND;VALUE=DATE:20340801
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT07071519)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Learn More About How Risankizumab Works in Young Participants W
 ith Ulcerative Colitis\nEstimated primary completion: July 2034. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07071519
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651281-2@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20371217
DTEND;VALUE=DATE:20371218
SUMMARY:tulisokibart: Phase 3 readout est. (NCT06651281)
DESCRIPTION:tulisokibart\, phase 3\, Ulcerative Colitis.\nStudy: Extension 
 Study of Long-term Safety and Efficacy of Tulisokibart in Participants Wit
 h Crohn's Disease or Ulcerative Colitis (MK-7240-011)\nEstimated primary c
 ompletion: 17 December 2037. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tulisokibart#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06651281
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
